Shares in Samsung BioLogics (KS: 207940) climbed 9% on Tuesday, as concerns over the firm being delisted due to accounting irregularities appeared to subside.
The uptick comes after the firm lost over 15% of its share price on Monday, as investors fretted that regulators, due to meet this week to discuss the matter, could take a dim view of the South Korean conglomerate's practices.
The Securities and Futures Commission (SFC), an auditing division of the country’s financial watchdog, the Financial Services Commission (FSC), will meet on Wednesday, but is now thought unlikely to order that the firm be delisted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze